[ 68 Ga]-DOTATATE PET Standardized Uptake Value Reduction after Bevacizumab in High-grade Meningioma: A Potential Treatment Response Biomarker.
Kellen Vo Vu, Hannah G Otis, Andrew Brandmaier et al.
✦ AI-curated · Sources linked
Case in brief
Three patients with biopsy-confirmed World Health Organization grade 3 meningioma received bevacizumab therapy and underwent baseline and follow-up [68 Ga]-DOTATATE PET imaging. All patients exhibited multifocal [68 Ga]-DOTATATE-avid lesions at baseline. Post-therapy, 67% of the lesions showed a reduction in maximum standardized uptake value (SUV max), indicating a potential treatment response. This suggests that [68 Ga]-DOTATATE PET may provide insights into treatment effects not captured by conventional MRI.
Diagnostic / clinical pearl
[68 Ga]-DOTATATE PET imaging may serve as a valuable tool for assessing treatment response in high-grade meningioma, particularly when conventional imaging shows minimal changes.
Why it matters
The findings suggest that [68 Ga]-DOTATATE PET could be a noninvasive biomarker for monitoring the efficacy of antiangiogenic therapies like bevacizumab in aggressive meningiomas.